Share Twitter LinkedIn Facebook Email Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Read here: https://jitc.bmj.com/content/8/1/e000673 Advertisement
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023] Immunotherapy 2 Mins Read
O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response – Anna M. Wu, MD – MOASC [2023] Immunotherapy 1 Min Read